Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
© Shutterstock

The Cambridge-based science company Kyttaro Limited has entered into a world-wide license agreement with Oxford University Innovation (OUI) to develop and commercialize an anti-inflammatory peptide technology platform that is based on naturally occurring proteins derived from ticks, viruses and other organisms that have evolved over millennia to target and inhibit key components of the human immune system.

This research work was led by Professor Shoumo Bhattacharya, and the platform technology was developed with funding received from the British Heart Foundation. The platform has the potential to treat a wide range of inflammatory conditions across multiple therapeutic areas including cardiovascular disease.

Atherosclerotic cardiovascular disease (ASCVD), such as coronary artery disease (CAD), are a leading cause of morbidity and mortality worldwide despite extensive use of existing ASCVD therapies (e.g. statins). It is estimated that CAD, which involves plaque formation in the blood vessels supplying the heart, is the most common heart disease in the US with 20M affected individuals and that CAD was responsible for c.360k US deaths in 2019.  Inflammation has been identified as a key risk factor in ASCVD that promotes disease progression and is associated with ASCVD-related complication. Emerging evidence from clinical studies showed that reducing inflammation on top of standard therapy has a clinical benefit and reduces cardiovascular events. 

Professor Shoumo Bhattacharya, Inventor of the technology and PI at the Radcliffe Department of Medicine, University of Oxford, stated: “I am looking forward to collaborating with the team at Kyttaro to accelerate the development of the anti-inflammatory platform technology that is based on naturally occurring proteins that have evolved in parasites for millions of years to circumvent the human’s body immune response. This technology offers hugely promising treatment options for inflammatory conditions including cardiovascular disease.”

Find out more. 

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Six new Associate Professor titles at RDM

Graham Collins, Betty Raman, Susie Shapiro, Christopher Toepfer, Stephen Twigg, and Adam Wilkinson have all been awarded Associate Professor titles

Two NHSBT research units launch at RDM

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford, with two of them led by RDM researchers.

Professor David Roberts elected Fellow of Academy of Medical Sciences

David Roberts, Professor of Haematology at the Radcliffe Department of Medicine and Consultant Haematologist, has been elected a Fellow of the Academy of Medical Sciences

REF 2021 outcomes